Accelerate Diagnostics (NASDAQ:AXDX) Rating Increased to Hold at StockNews.com

StockNews.com upgraded shares of Accelerate Diagnostics (NASDAQ:AXDX) from a sell rating to a hold rating in a research report released on Monday.

Accelerate Diagnostics Stock Performance

NASDAQ AXDX opened at $1.64 on Monday. Accelerate Diagnostics has a one year low of $0.73 and a one year high of $5.23. The company has a market capitalization of $41.07 million, a price-to-earnings ratio of -0.57 and a beta of 0.59. The company’s 50-day simple moving average is $1.79 and its two-hundred day simple moving average is $1.51.

Institutional Trading of Accelerate Diagnostics

A hedge fund recently raised its stake in Accelerate Diagnostics stock. Griffin Asset Management Inc. raised its stake in Accelerate Diagnostics, Inc. (NASDAQ:AXDX) by 1.9% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,380,654 shares of the medical research company’s stock after purchasing an additional 26,400 shares during the period. Griffin Asset Management Inc. owned 6.26% of Accelerate Diagnostics worth $1,615,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 17.14% of the company’s stock.

Accelerate Diagnostics Company Profile

Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.